Evidence map›Paper›PMID 40950721›Full record

ArticleiScience2025

CDC42-effector interaction inhibitors alter patterns of vessel arborization in skin and tumors

Linh M Vuong, Stephanie Hachey, Jessica Shiu, Danny F Xie, Noel Salvador, Nicoletta Brindani, Sine Mandrup Bertozzi, Maria Summa, Rosalia Bertorelli, Andrea Armirotti and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Linh M VuongDepartment of Dermatology, University of California, Irvine, Irvine 92697, CA, USA.
Stephanie HacheyDepartment of Molecular Biology and Biochemistry, University of California, Irvine, Irvine 92697, CA, USA.
Jessica ShiuDepartment of Dermatology, University of California, Irvine, Irvine 92697, CA, USA.
Danny F XieBeckman Laser Institute and Medical Clinic, University of California, Irvine, Irvine 92697, CA, USA.
Noel SalvadorDepartment of Biological Chemistry, University of California, Irvine, Irvine 92697, CA, USA.
Nicoletta BrindaniMolecular Modeling and Drug Discovery Lab, Istituto Italiano di Tecnologia, 16163 Genova, Italy.
Sine Mandrup BertozziAnalytical Chemistry Facility, Istituto Italiano di Tecnologia, 16163 Genova, Italy.
Maria SummaTranslational Pharmacology Facility, Istituto Italiano di Tecnologia, 16163 Genova, Italy.
Rosalia BertorelliTranslational Pharmacology Facility, Istituto Italiano di Tecnologia, 16163 Genova, Italy.
Andrea ArmirottiAnalytical Chemistry Facility, Istituto Italiano di Tecnologia, 16163 Genova, Italy.
Rachel PhamDepartment of Dermatology, University of California, Irvine, Irvine 92697, CA, USA.
Vance S H KuDepartment of Dermatology, University of California, Irvine, Irvine 92697, CA, USA.
Swara D LimbekarDepartment of Dermatology, University of California, Irvine, Irvine 92697, CA, USA.
Terry NguyenDepartment of Dermatology, University of California, Irvine, Irvine 92697, CA, USA.
Bernard ChoiBeckman Laser Institute and Medical Clinic, University of California, Irvine, Irvine 92697, CA, USA.
Christopher C W HughesDepartment of Molecular Biology and Biochemistry, University of California, Irvine, Irvine 92697, CA, USA.
Marco De VivoMolecular Modeling and Drug Discovery Lab, Istituto Italiano di Tecnologia, 16163 Genova, Italy.
Anand K GanesanDepartment of Dermatology, University of California, Irvine, Irvine 92697, CA, USA.

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI RICHARD A. VAN ETTEN · 1994 to 2026
$57.9M
UCI P30 Skin Center Systems Biology CoreP30AR075047 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI ANDERSEN, BOGI, GANESAN, ANAND K · 2019 to 2025
$5.1M
Identifying Therapeutic Targets for Stage III MelanomaR01CA244571 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI GANESAN, ANAND K · 2020 to 2024
$2.4M
NCI NIH HHS P30 CA062203NCI NIH HHS R01 CA244571NIAMS NIH HHS P30 AR075047
6 · The paper itself

Abstract

Skin tumors require a vascular supply to grow beyond 1 mm in depth, yet existing anti-angiogenesis agents are largely ineffective at treating melanoma tumors arising in skin. Using an approach that integrates antibody infusion, optical tissue clearing, multiphoton imaging, and vessel tracing, we identified the CDC42 GTPase RhoJ as a critical regulator of skin vessel arborization. Small molecules that target both RhoJ and CDC42 (CDC42 interaction inhibitors), but not those that target only CDC42 (CASIN), inhibit vessel branching in mouse skin

Indexed as

cancer;microenvironmentpharmacology

Identifiers

PMID40950721
PMCPMC12432855

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.